vs
Side-by-side financial comparison of PAMT CORP (PAMT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $141.3M, roughly 1.4× PAMT CORP). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -15.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-25.0M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -12.0%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PAMT vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $141.3M | $196.9M |
| Net Profit | $-29.3M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | -27.0% | 1.2% |
| Net Margin | -20.7% | — |
| Revenue YoY | -15.1% | 5.1% |
| Net Profit YoY | 7.4% | — |
| EPS (diluted) | $-1.38 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $141.3M | $196.9M | ||
| Q3 25 | $150.3M | $179.5M | ||
| Q2 25 | $151.1M | $181.1M | ||
| Q1 25 | $155.3M | $168.9M | ||
| Q4 24 | $166.5M | $187.3M | ||
| Q3 24 | $182.6M | $168.6M | ||
| Q2 24 | $182.9M | $178.0M | ||
| Q1 24 | $182.6M | $167.1M |
| Q4 25 | $-29.3M | — | ||
| Q3 25 | $-5.6M | $5.4M | ||
| Q2 25 | $-9.6M | $-4.8M | ||
| Q1 25 | $-8.1M | $4.8M | ||
| Q4 24 | $-31.6M | — | ||
| Q3 24 | $2.4M | $-143.5M | ||
| Q2 24 | $-2.9M | $18.9M | ||
| Q1 24 | $281.0K | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | -27.0% | 1.2% | ||
| Q3 25 | -3.8% | 3.5% | ||
| Q2 25 | -7.3% | 4.7% | ||
| Q1 25 | -5.9% | 1.2% | ||
| Q4 24 | -22.6% | 13.2% | ||
| Q3 24 | 1.3% | -82.8% | ||
| Q2 24 | -0.4% | 15.9% | ||
| Q1 24 | -0.4% | 7.9% |
| Q4 25 | -20.7% | — | ||
| Q3 25 | -3.7% | 3.0% | ||
| Q2 25 | -6.4% | -2.7% | ||
| Q1 25 | -5.2% | 2.8% | ||
| Q4 24 | -19.0% | — | ||
| Q3 24 | 1.3% | -85.1% | ||
| Q2 24 | -1.6% | 10.6% | ||
| Q1 24 | 0.2% | 5.4% |
| Q4 25 | $-1.38 | $0.05 | ||
| Q3 25 | $-0.27 | $0.12 | ||
| Q2 25 | $-0.46 | $-0.11 | ||
| Q1 25 | $-0.37 | $0.10 | ||
| Q4 24 | $-1.44 | $0.38 | ||
| Q3 24 | $0.11 | $-3.11 | ||
| Q2 24 | $-0.13 | $0.39 | ||
| Q1 24 | $0.01 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $83.7M | $238.4M |
| Total DebtLower is stronger | $333.9M | $372.2M |
| Stockholders' EquityBook value | $210.5M | $693.1M |
| Total Assets | $697.9M | $1.3B |
| Debt / EquityLower = less leverage | 1.59× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.7M | $238.4M | ||
| Q3 25 | $115.6M | $246.3M | ||
| Q2 25 | $117.3M | $445.9M | ||
| Q1 25 | $102.7M | $493.6M | ||
| Q4 24 | $110.7M | $484.6M | ||
| Q3 24 | $92.3M | $453.8M | ||
| Q2 24 | $114.0M | $404.2M | ||
| Q1 24 | $125.8M | $325.9M |
| Q4 25 | $333.9M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $325.6M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $210.5M | $693.1M | ||
| Q3 25 | $239.5M | $727.2M | ||
| Q2 25 | $244.9M | $757.8M | ||
| Q1 25 | $269.6M | $798.5M | ||
| Q4 24 | $277.5M | $778.3M | ||
| Q3 24 | $308.9M | $749.6M | ||
| Q2 24 | $306.7M | $879.3M | ||
| Q1 24 | $314.6M | $892.2M |
| Q4 25 | $697.9M | $1.3B | ||
| Q3 25 | $715.2M | $1.3B | ||
| Q2 25 | $707.9M | $1.5B | ||
| Q1 25 | $712.6M | $1.6B | ||
| Q4 24 | $741.7M | $1.6B | ||
| Q3 24 | $756.7M | $1.5B | ||
| Q2 24 | $733.5M | $1.6B | ||
| Q1 24 | $746.4M | $1.6B |
| Q4 25 | 1.59× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 1.17× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $43.7M |
| Free Cash FlowOCF − Capex | $-25.0M | $43.5M |
| FCF MarginFCF / Revenue | -17.7% | 22.1% |
| Capex IntensityCapex / Revenue | 13.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-23.4M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.8M | $43.7M | ||
| Q3 25 | $5.9M | $60.8M | ||
| Q2 25 | $12.2M | $12.0M | ||
| Q1 25 | $5.0M | $35.5M | ||
| Q4 24 | $15.2M | $33.1M | ||
| Q3 24 | $15.5M | $53.9M | ||
| Q2 24 | $18.7M | $53.2M | ||
| Q1 24 | $9.6M | $49.1M |
| Q4 25 | $-25.0M | $43.5M | ||
| Q3 25 | $2.5M | $57.0M | ||
| Q2 25 | $5.9M | $9.3M | ||
| Q1 25 | $-6.8M | $26.9M | ||
| Q4 24 | $-39.9M | $31.0M | ||
| Q3 24 | $-33.6M | $49.8M | ||
| Q2 24 | $4.1M | $51.6M | ||
| Q1 24 | $-12.2M | $46.3M |
| Q4 25 | -17.7% | 22.1% | ||
| Q3 25 | 1.7% | 31.7% | ||
| Q2 25 | 3.9% | 5.1% | ||
| Q1 25 | -4.4% | 15.9% | ||
| Q4 24 | -24.0% | 16.6% | ||
| Q3 24 | -18.4% | 29.6% | ||
| Q2 24 | 2.2% | 29.0% | ||
| Q1 24 | -6.7% | 27.7% |
| Q4 25 | 13.6% | 0.1% | ||
| Q3 25 | 2.3% | 2.2% | ||
| Q2 25 | 4.2% | 1.5% | ||
| Q1 25 | 7.6% | 5.1% | ||
| Q4 24 | 33.1% | 1.1% | ||
| Q3 24 | 26.9% | 2.4% | ||
| Q2 24 | 8.0% | 0.9% | ||
| Q1 24 | 12.0% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.44× | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | 34.11× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
